Oral psoriasis treatment SFA-002 improves disease severity within 6 weeks

Key takeaways:

• 85% of patients achieved PASI 50, 71% achieved PASI 75 and two achieved PASI 100.
• No drug-related adverse events or toxicities were observed.

Based on results from a phase 1b trial, SFA-002 improved the signs and symptoms of chronic plaque psoriasis in patients within 6 weeks, SFA Therapeutics announced in a press release.

SFA-002 is an oral pill that down-regulates levels of pro-inflammatory cytokines involved in the pathogenesis of psoriasis including tumor necrosis factor-alpha, interferon‐gamma and multiple interleukin pathways.

The announced results are from the first cohort of the company’s phase 1b trial evaluating the effects of SFA-002 in patients with mild to moderate chronic plaque psoriasis.

The results are based on outcomes from 12 weeks of active therapy and a 1-month follow-up in 14 patients, as well as a 12-week extension period that included six of the patients.

Results showed that 85% of patients achieved PASI 50 or greater, 71% achieved PASI 75 or greater and two patients achieved PASI 100.

Improvement was observed within 6 weeks of treatment with no drug-related adverse events or toxicities emerging during active treatment or after the follow-up.

The phase 1b trial is ongoing with the second cohort currently being evaluated. Results from the second cohort are expected by the end of 2023.